SCHEMBL562413

SCHEMBL562413

NC1=NS(=O)(=O)Nc2nc(-c3ccccc3)[nH]c21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 6/20 0.43
MAPK12 P53778 6/20 0.43
MAPK11 Q15759 6/20 0.43
MAPK14 Q16539 6/20 0.43
GCGR P47871 3/20 0.43
MAPT P10636 4/20 0.42
ALDH1A1 P00352 3/20 0.42
HPGD P15428 3/20 0.42
KMT2A Q03164 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MEN1 O00255 2/20 0.42
RAF1 P04049 3/20 0.42
MAPK9 P45984 2/20 0.42
GAA P10253 3/20 0.40
KDM4E B2RXH2 3/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
GLA P06280 2/20 0.40
HTT P42858 1/20 0.40
GFER P55789 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16503585 0.88 MEN1 (0.42) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL563130 0.85 MAPT (0.46) MAPTALDH1A1HPGDKMT2ASMN1; SMN2
SCHEMBL561997 0.82 CDK5 (0.36)
SCHEMBL563170 0.81 NPC1 (0.44) MAPK14ALDH1A1GAANPC1RAB9A
SCHEMBL562125 0.76 PNP (0.42) MAPTKMT2AGAAKDM4E
SCHEMBL563259 0.75 RAB9A (0.42) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL563667 0.70 PDE5A (0.41) MAPK13MAPK12MAPK11MAPK14MAPT
SCHEMBL8803154 0.69 XDH (0.38) MAPTALDH1A1HPGDKMT2ASMN1; SMN2
SCHEMBL8800858 0.69 ATR (0.41) NPC1RAB9A
SCHEMBL563044 0.68 ADORA3 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815846-B2 Family of antichagasics derived from imidazo[4,5-C][1,2,6]thiadiazine 2,2-dioxide UNIVERSIDAD DE LA REPUBLICA DE URUGUAY (UY) 2014-08-26 US claimed
US-20120035160-A1 NEW FAMILY OF ANTICHAGASICS DERIVED FROM IMIDAZO[4,5-C][1,2,6]THIADIAZINE 2,2-DIOXIDE UNIVERSIDAD DE LA REPUB'LICA URUGUAY (UY) 2012-02-09 US claimed
EP-2392577-A1 NEW FAMILY OF ANTICHAGASICS DERIVED FROM IMIDAZO[4,5-C][1,2,6]THIADIAZINE 2,2-DIOXIDE Consejo Superior de Investigaciones Científicas (CSIC) (ES) 2011-12-07 EP claimed
US-8815846-B2 Family of antichagasics derived from imidazo[4,5-C][1,2,6]thiadiazine 2,2-dioxide UNIVERSIDAD DE LA REPUBLICA DE URUGUAY (UY) 2014-08-26 US disclosed
US-20120035160-A1 NEW FAMILY OF ANTICHAGASICS DERIVED FROM IMIDAZO[4,5-C][1,2,6]THIADIAZINE 2,2-DIOXIDE UNIVERSIDAD DE LA REPUB'LICA URUGUAY (UY) 2012-02-09 US disclosed
EP-2392577-A1 NEW FAMILY OF ANTICHAGASICS DERIVED FROM IMIDAZO[4,5-C][1,2,6]THIADIAZINE 2,2-DIOXIDE Consejo Superior de Investigaciones Científicas (CSIC) (ES) 2011-12-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035160-A1 NEW FAMILY OF ANTICHAGASICS DERIVED FROM IMIDAZO[4,5-C][1,2,6]THIADIAZINE 2,2-DIOXIDE THOC2, TUBGCP2, TBC1D5 MAPK13 3752/4885MAPK12 2568/4885MAPK11 3889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.